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Background: Adrenocortical carcinoma is a rare cancer, with an incidence in the literature of 0.5 to 2 cases per
million population per year. Adult adrenocortical carcinoma has a poor prognosis, underscoring the importance of
identifying diagnostic and prognostic markers.
Methods: We searched our laboratory database for all cases in the past 15 years with a diagnosis of adrenocortical
carcinoma. The original slides were then reviewed for their histopathological features. A representative paraffin
block was subjected to further immunohistochemical staining for Ki-67, inhibin, steroidogenic factor-1 (SF-1), p53,
and Β-catenin. These slides were scored by the study pathologist who was blinded to all clinicopathological data.
In addition, a comprehensive review of the relevant English literature in the past 15 years was conducted.
Results: Eight cases were identified, including two adrenal sarcomatoid carcinomas. Seven of the eight cases had a
disrupted reticulin network. Six of the eight tumors had >10% Ki-67 expression. Five of the eight tumors had >10%
p53 expression. Positive inhibin immunohistochemical staining was seen in three of the eight tumors, and positive
SF-1 staining was seen in five of the seven stained tumors. Abnormal Β-catenin intracellular accumulation was noted
in four of the eight tumors. The two tumors in our series with sarcomatoid histology did not stain positively for SF-1 or
inhibin.
Conclusions: Eight cases of adrenocortical carcinoma, including two with sarcomatoid features are presented. The two
sarcomatoid adrenocortical carcinomas in our series did not stain for SF-1 which suggests a possible de novo pathway
of tumorigenesis for this rare variant. The reticulin staining method was a useful tool for rapid differentiation of
adrenocortical adenomas and carcinomas. Diffuse p53 staining showed a trend for positive correlation with
increased Ki-67 expression. Inhibin staining was inconsistently expressed in our cases of adrenocortical carcinoma.
In conclusion, as adrenocortical carcinoma is a rare disease, we recommend future multicenter studies with
appropriate sample sizes to further evaluate the efficacy of these diagnostic and prognostic markers.
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Adrenocortical carcinoma (ACC) is rare and has a poor
prognosis. Even for patients with resected tumors, the
median survival is only 32 months in the United States
[1]. While ACC is uncommon with an annual incidence
of 0.5 to 2.0 per million people, adrenal incidentalomas* Correspondence: rani.kanthan@saskatoonhealthregion.ca
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unless otherwise stated.are increasingly being recognized, due to the availability of
superior imaging techniques, with a reported prevalence
of 3% to 4% on abdominal CT scan [1-5]. Most adrenal
incidentalomas are benign, while most malignant adrenal
tumors are metastatic in origin [6]. As such, accurate diag-
nosis of malignant adrenocortical tumors, particularly
distinguishing ACC from adrenal adenomas, is essential
for management; however, accurate diagnosis continues
to remain a challenge. There are continued significant
areas of uncertainty regarding pathogenesis and risk as-
sessment. In this context, several histopathological andentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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past two decades as additional adjuncts that include
markers, such as steroidogenic factor-1 (SF-1) that may
be useful in establishing the adrenocortical origin of an
adrenal mass, while other markers, such as Ki-67 and
p53, could help stratify tumors into prognostic groups.
The aim of this study is to discuss the diagnostic and
prognostic features of ACC through a series of cases
treated at our institution over a 15-year period in the
context of a comprehensive relevant literature review.
We compared immunohistochemical expression profiles
of Ki-67, inhibin, SF-1, p53, and Β-catenin with histo-
pathological features and patient outcome.
Methods
Pathological review
All patients in the Saskatoon Health Region Department
of Pathology Laboratory Information System with a
pathological diagnosis of adrenocortical carcinoma from
1998 to 2013 were identified. All cases were reviewed on
a routine hematoxylin-eosin-stained slide according to
the Weiss criteria to confirm the presence of ACC.
Immunohistochemical studies using antibodies to Ki-67,
B-catenin, SF-1, and p53 were performed on a representa-
tive deparaffinized tissue section by the avidin-biotin-
peroxidase complex (ABC) technique after antigen retrieval
using appropriate positive and negative controls in all cases.
Negative controls were obtained by omission of the primary
antibody from the staining procedure. The antibodies used
with their sources, clones, antigen-retrieval techniques, and
dilutions are listed in Table 1.
Immunohistochemically stained slides were analyzed
in the standard semi quantitative basis incorporating the
intensity of the staining (mild, moderate, strong) coupled
with the percentage of positively stained cells in a four-
point scale: 0, no stain (up to 10% positive cells); 1, light
(11% to 25% positive cells); 2, moderate (26% to 50%
positive cells); 3, heavy (51% to 75% positive cells) and;
4, intense stain (76% to 100% positive cells). The cellsTable 1 Antibodies used in this study
Antibody Company and
clone
Target retrieval solution (TRS) Detectio
Beta
catenin
Dako, B-catenin-1 High Flex
Inhibin Dako, R1 High Flex
Ki67 Dako, MIB1 High Flex
Ki67 decal Dako, MIB1 High Flex
p53 Dako, D0-7 High Flex




IgG1, immunoglobulin G1; SF-1, steroidogenic factor-1.were considered positive when more than 10% of them
were stained with the respective antibodies. The reticulin
framework of the tumors was examined by histochem-
ical staining. The study pathologist was blinded to any
clinical information prior to pathological review and in-
terpretation for the purpose of this study.
The hospital charts for all patients were obtained and
data was collected on age, sex, mode of presentation of
the tumor, and available follow-up.
Upon application, this study was exempt from ethical
approval by the University of Saskatchewan Biomedical
Ethics Review Board.
Literature review
A literature search using the National Library of Medi-
cine Interface PubMed was conducted using the search
terms ‘adrenocortical carcinoma’ and ‘adrenal cortical
carcinoma’ which was limited to the English language
from 1999 to present. The bibliographies of these manu-
scripts further identified relevant secondary sources.
A detailed review of the published large case series
was undertaken. Large case series were defined as those




From an initial search list of 15 cases of possible ACC,
eight patients with a ‘bonafide’ histopathological diagno-
sis of adrenocortical carcinoma were identified using the
Weiss criteria as a guideline for diagnosis. There were
five females and three males with an average age at diag-
nosis of 53.5 years (range 25 to 79).
Necrosis was the most common histopathological fea-
ture, found in six of eight tumors. Vascular invasion was
identified in five of eight, marked nuclear pleomorphism
in two of eight, and capsular invasion in one of eight. In-
creased mitotic rate greater than 5/50 high-powered fields
(HPFs) was seen in seven cases. Atypical mitoses weren Dilution Link to spec sheet
1:200 Monoclonal mouse anti-human beta-catenin,
clone β-catenin-1
1:5 Monoclonal mouse anti-human inhibin α, clone R1
1:50 Monoclonal mouse anti-human Ki-67 antigen,
clone MIB-1
1:20 Same as above
1:100 Monoclonal mouse anti-human p53 protein, clone
DO-7
ision + 1:150 Monoclonal mouse [Mm] IgG1 anti-human clone
N1665
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tecture. Venous and sinusoidal invasion were present in
five of the eight cases. In summary, seven cases had more
than four Weiss criterion thereby meeting the histological
criteria for ACC. In one case, though there was diffuse
architecture with high grade nuclei and increased mitoses,
diffuse necrosis, atypical mitoses, capsular, sinusoidal, or
venous invasion were not identified. Reticulin staining re-
vealed loss of the reticulin network in seven of the eight tu-
mors. Ki-67 was overexpressed in all of the cases. Aberrant
nuclear staining for p53 was noted in all but one case.
Increased intracellular accumulation of Β-catenin was
present in 50% of the cases. Three of the eight tumors had
positive immunohistochemical staining for inhibin. Five of
the eight tumors stained positively for SF-1, while two were
negative, and one did not have adequate tissue available for
staining. The results of immunohistochemical staining are
summarized in Table 2.
Two of the eight patients had tumors with sarcomatoid
features. Interestingly, lack of SF-1, inhibin, and aberrant
Β-catenin expression was noted in the sarcomatoid re-
gions of these tumors.
Clinical review
Seven of the eight patients had surgical resection. One pa-
tient presented with metastatic disease identified as ACC
on lung biopsy. The median length of follow-up was
8 months (range 0.8 to 60.2). The most common presenta-
tion was an incidentally discovered mass during imaging
(six of eight patients). One patient was presented with
Cushing’s syndrome, and one was presented with symp-
toms related to metastatic lung disease. Three patients
experienced recurrence, 2.3 to 6.5 months after resection.
Of the four patients who died, three died with metastatic
ACC and one died due to other medical comorbidities
without ever having identified disease recurrence. The clin-
ical data for all of the patients are summarized in Table 3.
Sarcomatoid cases
Case 3 in Tables 2 and 3 is a 65-year-old male who, dur-
ing work-up for claudication, was found incidentally toTable 2 Results of immunohistochemical staining for eight pa
Case number Age Sex Ki-67 (%) Β-catenin intracellu
1 59 M 80 Present
2 25 F 40 Present
3 65 M 20 Absent
4 66 F 50 Absent
5 79 M 10 Present
6 34 F 85 Present
7 68 F 60 Absent
8 32 F 10 Absent
F, female; M, male; SF-1, steroidogenic factor-1.have a large adrenal mass as well as a renal mass. He
had an open radical nephrectomy. The suprarenal tumor
measured 12.8 × 8.9 × 7.5 cm. Microscopically, the supra-
renal tumor was composed of solid sheets of epithelioid
cells with abundant eosinophilic cytoplasm and spindled
cells, which in some areas formed a fascicular growth
pattern as seen in Figure 1. There was marked nuclear
pleomorphism including occasional malignant multinucle-
ated giant cells. There was no heterologous differentiation
although a few cells had eosinophilic rhabdoid-like glob-
ules. Both typical and atypical mitoses were identified with
an average of 20 mitoses per 20 HPF as seen in Figure 1b.
Based on WHO recommendations, this tumor with a
spindled morphology qualified for being a sarcomatoid
variant [7].This patient remains disease-free at 4 months.
Case 7 in Tables 2 and 3 is a 68-year-old lady who was
incidentally found to have a large adrenal tumor during
follow-up imaging for a previous lung adenocarcinoma.
She had a radical nephrectomy. The adrenal tumor mea-
sured 13.0 × 11.0 × 9.0 cm. Microscopically, much of the
tumor was hemorrhagic and necrotic. The neoplasm
showed marked pleomorphism with frequent multinucle-
ated giant cells as seen in Figure 2a. There were epithelioid
areas and sarcomatoid areas with spindled cells in a
myxomatous background as seen in Figure 2b. There
were numerous typical mitoses, five per single HPF in
some areas, and atypical mitoses. In agreement with
WHO recommendations, this is a sarcomatoid carcin-
oma [7]. This patient had disease recurrence invading
the gastroduodenal artery within 68 days. She required
multiple transfusions and embolization of the artery for
control of bleeding. She succumbed to her disease
223 days after initial surgery.
Discussion
Epidemiology and clinical presentation
Adrenocortical carcinoma is a rare malignancy with an
annual incidence of 0.5 to 2.0 per million people with a
female-to-male ratio of 1.2 to 1.5:1 [1-4]. The average age
of presentation reported by Bilimoria et al. (n = 3,982) and
Kutikov et al. (n = 4275) in the United States Nationaltients with adrenocortical carcinoma









Table 3 Clinical data for eight patients with adrenocortical carcinoma
Case number Age Sex Presentation Time to recurrence (days) Time to death (days)
1 59 M Cushingoid N/A N/A
2 25 F Incidentally 119 N/A
3 65 M Incidentally N/A N/A
4 66 F Metastatic 0 25
5 79 M Incidentally N/A 353
6 34 F Incidentally 195 254
7 68 F Incidentally 68 223
8 32 F Incidentally N/A N/A
F, female; M, male; N/A, not available.
Wanis and Kanthan World Journal of Surgical Oncology  (2015) 13:117 Page 4 of 13Cancer Data Base is 55 years [1,4]. This is similar to the
average age in our case series of 53.5 years. The demo-
graphic information from the five largest published case
series (n > 300, from unique databases) on ACC, is tabu-
lated in Table 4 [1-4,8-14].
Cases series with data from identical databases were
not included. In this manuscript, we have elected to
tabulate publications with the largest n from their inde-
pendent databases. In this context, the following studies
that are not represented are as follows: Bilimoria et al.
(National Cancer Database, n = 3,982) [1], Lughezzani et
al. (SEER, n = 573) [11], Sturgeon et al. (SEER, n = 457)
[12], Johanssen et al. (German ACC Registry, n = 387)
[13], and Tran et al. (SEER, n = 320) [14]. ACC, adreno-
cortical carcinoma.
Pediatric ACCs have several important differences com-
pared to adult ACCs. The incidence in children is much
lower with only 25 new cases of ACC being diagnosed in
the USA every year [15]. The incidence for children is
greatest in the first year of life [16]. ACC is more common
than adrenocortical adenoma in children (approximately
3:1 in newborns and 2:1 in older children) [17,18]. The
clinical presentation of these tumors in children is also
different with more pediatric patients presenting with
symptoms of adrenal hormone hypersecretion. The most
common presentation in children is virilization, followedFigure 1 Photomicrograph showing (a) epithelioid spindled cells wi
(b) increased mitotic activity (*) with typical and atypical mitoses.by Cushing’s syndrome [19]. In fetal and newborn pa-
tients, the main presentation was an abdominal mass
found on physical examination or antenatal sonography,
but this is followed closely by virilization [18]. However,
pathological diagnosis of pediatric ACC is more chal-
lenging because frequently used adult histopathological
criteria, such as the Weiss criteria, have not been
shown to accurately predict tumor behavior in children
and therefore their use is not recommended. Instead,
adrenocortical tumors in children should be classified
as clinically benign or clinically malignant based on
their clinical course [15]. Outcomes in children are bet-
ter than in adults, with a reported 5-year overall sur-
vival of 57%, which is even higher (91.1%) in patients
under the age of 5 [16].
Clinical presentation of ACC is variable. While most
ACCs are biochemically functional, in many patients this
does not manifest clinically, and a large proportion of
tumors are discovered incidentally or are metastatic at
the time of presentation [20-22], with the most common
sites of distant metastasis being, in decreasing frequency,
the liver, lungs, and bone [1]. In our series, six out of
eight patients presented with incidentally discovered tu-
mors, and only one patient had metastatic disease on pres-
entation. One patient presented with Cushing’s syndrome.
The reported proportion of functioning ACC varies in theth abundant eosinophilic cytoplasm in a fascicular pattern and
Figure 2 Photomicrograph showing (a) malignant cells with marked nuclear pleomorphism (#) and the presence of a multinucleated
tumor giant cell (*) and (b) sarcomatoid areas with spindled cells in a myxomatous background.
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tional tumors secrete cortisol [20-22].
Diagnosis
Imaging
While imaging is not able to definitively diagnose malig-
nancy in an adrenal mass, modern modalities can cor-
rectly differentiate adrenal masses before histopathological
diagnosis in most cases. The most obvious characteristic
noted on cross-sectional imaging of an adrenal mass is the
size of the lesion. A cut-off of 4 cm has a sensitivity of
93% for identifying adrenal carcinoma and, while this is a
conservative size cut-off, it should be used due to the ag-
gressive nature of ACC and the importance of early diag-
nosis [5]. Higher cut-offs of 5 or 6 cm have been
suggested with sensitivities of 90% or greater in smaller
studies [23,24]. Beyond size, few other features of the mass
on unenhanced and contrast-enhanced CT help to steer
accurate radiographic identification. The density of the
adrenal lesion has been proposed as a valuable tool,
and benign adenomas tend to be more lipid-rich and
have Hounsfield unit densities less than 10 [23,25].
Tumor extension into the IVC with a tumor thrombus
is seen in a proportion of tumors, particularly in right-
sided tumors, and is indicative of malignancy. On
contrast-enhanced CT, little enhancement is seen in
the central necrosis of malignant tumors compared to
the peripheral tumor [24,25]. Lastly, on contrast-
enhanced imaging, the relative percentage of contrast
agent enhancement washout seen in malignant tumors
after 15 min is generally less than 40% [24-26]. Abdominal
CT can be combined with chest imaging in order to estab-
lish the presence of any metastatic lung disease. The effi-
cacy of MRI is relatively equivalent to that of CT and in
patients where radiation is not a concern, CT scan is
recommended as the initial radiographic modality [21,23].
Since not all patients with functioning tumors present
with symptoms of hormonal excess, a careful endocrine
work-up should be performed and the absence ofsecretion should alert clinicians to the possibility that
the mass is not an ACC [20,21]. In contrast, adrenal
adenomas are less likely to be functioning and are gener-
ally significantly smaller than adrenal carcinomas when
discovered incidentally [5].
Biopsy of adrenal masses has a low diagnostic accuracy
and may promote needle track metastases. As such, biopsy
is not suggested as part of the diagnostic work-up except
in patients with metastatic disease, not scheduled for sur-
gery, in whom the diagnosis remains unestablished or in
patients with a suspicious endocrine-inactive adrenal mass
and a history of an extra-adrenal malignancy [21]. In
patients who do not meet these conditions, biopsy of
the adrenal mass unnecessarily delays the diagnosis of
malignancy.
Histopathology
Three histopathological scoring systems for distinguishing
benign from malignant ACCs have been proposed. The
Hough system employs 12 criteria, 7 histologic and 5 non-
histologic. Each criterion is assigned a numeric value, and
the total score is predictive of the biologic behavior of the
tumor [27]. The Hough criteria are tabulated in Table 5.
Slooten et al. have also proposed a scoring system [28].
Their system includes seven histological criteria and no
non-histological criteria. In contrast to the Hough system,
the Slooten criteria are not limited by the availability of
clinical findings. The Slooten system also assigns numeric
values to its criteria and a total value greater than eight is
correlated with tumor behavior [27]. The Slooten criteria
are tabulated in Table 6.
The Weiss criteria introduced in 1984 [29], later revised
[30], and then modified in 2002 [31], are the current
standard of practice to establish the diagnosis of ACC.
Histopathological diagnosis of ACC is made when tumors
meet three of the nine Weiss criteria as listed below
[21,30,32]: 1) grade 3 or 4 nuclear grade (enlarged, oval to
lobulated nuclei with coarsely granular to hyperchromatic
chromatin and easily discernible, prominent nucleoli); 2)
Table 4 Largest ACC case series published to date (n > 300)
Reference Published
year








Proportion of tumors with
distant metastasis at
presentation (%)
Kutikov et al. [4] 2011 United States National Cancer Database 4,275 54.5 41.9% to 58.1% 11.5 34.4
Kebebew et al. [3] 2006 United States Surveillance, Epidemiology, and End Results
(SEER) Database
725 51.2 45.9% to 54.1% 12 34.8
Fassnacht et al. [8] 2009 Germany The German ACC Registry 416 46.7 37.3% to 62.7% 11.3 29.3
Else et al. [9] 2014 United States Michigan Endocrine Oncology Repository 391 47.4 40% to 60% 11.8 29
Kerkhofs et al. [2] 2013 Netherlands Netherlands Cancer Registry 359 56 45% to 55% Not available 35
Ayala-Ramirez et al. [10] 2013 United States Tumor Registry Database at the University of
Texas MD Anderson Cancer Center















Table 5 Hough system criteria
Criteria Numeric value
Histological
Diffuse growth pattern 0.92
Vascular invasion 0.92
Tumor cell necrosis 0.69
Broad fibrous bands 1.00
Capsular invasion 0.37
Mitotic index (>1/10 HPFs) 0.60
Pleomorphism 0.39
Nonhistologic
Tumor mass (>100 g) 0.60
Urinary 17-ketosteroids (10 mg/1 g creatinine 24 h) 0.50
Response to ACTH (17-hydroxysteroids increased two
times after 50 mcg of IV ACTH)
0.42
Cushing syndrome with virilism, virilism alone, or no
clinical manifestations
0.42
Weight loss (>10 lb/3 months) 2.00
ACTH, adrenocorticotropic hormone; HPFs, high-powered fields.
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cells comprising 25% or less of the tumor; 5) diffuse archi-
tecture greater than one third of the tumor; 6) necrosis; 7)
invasion of venous structures; 8) invasion of sinusoidal
structures; and 9) invasion of the tumor capsule.
To simplify the Weiss system, while retaining diagnostic
value and improving interobserver reliability, a revised
system was proposed by Aubert et al. [31]. Their system
requires assessment of only five Weiss criteria: i) mitotic
grade, ii) percent of clear cells comprising the tumor, iii)
abnormal mitoses, iv) necrosis, and v) capsular invasion.
Though the total Weiss score has been shown to have
high interobserver agreement [31], the interobserver
reliability of individual criteria has been criticized [27,33].
In particular, nuclear grade, proportion of clear cells, and
architectural assessment may have high variability among
different observers. Recently, the reticulin method simpli-
fies the Weiss system. This method requires histochemical
staining for reticulin with microscopic examination of theTable 6 van Slooten criteria
Criteria Numeric value
Regressive changes such as necrosis, hemorrhage,
fibrosis, or calcification
5.7
Loss of normal structure 1.6
Nuclear atypia 2.1
Nuclear hyperchromasia 2.6
Abnormal nucleoli structure 4.1
Mitotic activity >2/10 HPFs 9.0
Capsular or vascular invasion 3.3
HPFs, high-powered fields.reticulin/basal membrane network. Any tumor with a
disrupted reticulin framework as well as the presence of
mitosis >5/50 HPFs, necrosis, or venous invasion meets
the algorithm’s criteria and is considered malignant [34].
This most recent algorithm has been validated and is
shown to have relatively high interobserver agreement
[33], albeit lower than reported for the total Weiss score
[31]. In light of this finding, we stained specimens in our
study for reticulin and seven of the eight tumors had a dis-
rupted reticulin framework. On blinded review, the tumor
which had an intact reticulin framework (case 5) also
lacked Weiss criteria on examination by the study patholo-
gist. Having been initially reported as having diffuse necro-
sis, >5 mitotic figures per 50 HPFs, and capsular invasion,
these histological features were not seen on re-examination
of select slides. Furthermore, the tumor weighed only 46 g
(4.7 cm). Therefore, whether this tumor truly represents an
adrenal carcinoma remains debatable. Unfortunately,
clinical correlation was impossible in this patient
because they died of unrelated causes within 1 year of
initial diagnosis. An incorrect initial diagnosis is not
uncommon in adrenocortical carcinoma. A large audit
of cases in Germany identified a high histopathological
misclassification rate of 13% [13].
Immunohistochemistry
TP53 The TP53 tumor suppressor gene, linked with
La-Fraumeni syndrome, is frequently mutated in cancers,
including adrenocortical carcinoma. In Southern Brazil,
the incidence of adrenocortical tumors is unusually high,
coinciding with a high prevalence of the germ line TP53
mutation R337H which is present in up to 0.5% of new-
borns in specific regions of Southern Brazil [35]. Carriers
of this particular mutation have been found to have a
penetrance of 2.39% to 9.9% for adrenocortical tumors
[35,36], with most tumors being carcinomas [35]. Inter-
estingly, this particular TP53 mutation was not found
to predispose to extra-adrenal cancers, although this
relationship was not studied rigorously [36]. In Caucasian
patients with ACC, TP53 germ line mutation analysis has
revealed a frequency of 3.9% in adult patients which
suggests a specific role for TP53 in ACC tumorigenesis
[37]. Loss of heterozygosity of 17p13, on which TP53 is
encoded, is studied as a valuable diagnostic marker. In one
series, 74% of ACCs, compared with 14% of adenomas,
had loss of heterozygosity at 17p13 [38]. Gicquel et al. also
noted the value of 17p13 loss of heterozygosity as an inde-
pendent predictor of disease-free survival [39].
Immunohistochemical staining for p53 expression in
ACC has found aberrant nuclear staining in a varying
proportion of carcinomas, 5% to 60% [40-42]. As such,
use of p53 expression to help distinguish benign from
malignant adrenal tumors may be an important adjuvant
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larly true since aberrant expression is extremely rare in
adenomas [41-43]. Patients with increased p53 staining
tend to have higher grade tumors, reflected by higher
Ki-67 expression, higher tumor stage, and poorer
disease-free survival [44]. However, p53 has not been
shown to be related to overall survival [44], and its cor-
relation with poor clinical outcomes is likely due to its
association with higher tumor grade. In our series, five
of the eight tumors had >10% cells with aberrant expres-
sion of p53, and the two cases with highest aberrant p53
expression (>85%) also had the highest proliferative
activity (Ki-67 > 80%).
SF-1 SF-1 expression is specific to the adrenal cortex
[45]. It plays an important role in adrenal development
and remains expressed into adulthood [46]. Conse-
quently, adrenal tumorigenesis is influenced by the pro-
liferative effect of SF-1, and SF-1 overexpression has
been shown in tumors originating from the adrenal
cortex [45,47]. In particular, this has been noted in child-
hood adrenal tumors where an increased copy of the SF-
1 gene is associated with tumorigenesis [48,49].
SF-1 immunohistochemical staining has particular
clinical value because its expression has high sensitivity
and specificity in determining adrenocortical origin of
an adrenal mass [45]. As such, it should be used to
differentiate adrenal masses [21]. Interestingly, SF-1 has
been found to have independent prognostic value in
multivariate analysis. Strong SF-1 expression is associ-
ated with poor clinical outcome in ACC even after ad-
justment for stage [45,47]. In the future, the utility of
SF-1 may extend to treatment. Inverse agonists of SF-1
have been studied in vitro on human ACC cells with
success and may have some clinical utility, although this
is yet to be trialed [50].
Five out of eight of our cases stained positively for SF-1.
Interestingly, case 3 and 7, which were histologically sar-
comatoid, did not stain for SF-1 in the sarcomatoid areasFigure 3 Photomicrograph of SF-1 stained slide showing (a) adreno
(b) sarcomatoid region of adrenocortical carcinoma with absent staof the tumors. This is shown in Figure 3a,b. Given the role
of SF-1 in adrenocortical cellular development, the lack of
SF-1 staining in sarcomatoid adrenal tumors suggests an
alternative pathway of development for these tumors.
These findings suggest that sarcomatoid adrenocortical
carcinoma may arise from a de novo rather than a dediffer-
entiation mechanism. SF-1 staining was unfortunately not
performed in other published cases of sarcomatoid ACC.
This finding needs to be confirmed in the future, poten-
tially in a meta-analysis of published sarcomatoid ACC
cases with SF-1 staining.
Β-catenin Wnt/Β-catenin signaling is thought to be inte-
gral to adrenal gland cellular growth and regulation [51].
Activation of this pathway has been shown to be an im-
portant factor in tumorigenesis in both benign and malig-
nant tumors of the adrenal cortex [21,51,52]. Β-catenin is
normally found on the plasma membrane, associated with
E-cadherins, or in the cytoplasm and nucleus where its ac-
cumulation influences the Wnt signaling pathway. When
accumulation is abnormally increased due to activating
mutations, there is abnormal Wnt pathway activation
resulting in tumor formation [51]. This has been demon-
strated in a mouse model, where constitutive activation of
Β-catenin in the adrenal glands has been shown to induce
adrenocortical cell hyperproliferation and loss of differen-
tiation [53]. In the older mice, this process resulted in
malignant transformation [53].
Immunohistochemical staining for Β-catenin can iden-
tify abnormal activation, demonstrated as cytoplasmic or
nuclear staining. Both adenomas and carcinomas have
been shown to have abnormal Β-catenin staining, with
more diffuse and frequent immunostaining in malignant
tumors [54]. Abnormal Β-catenin staining has been asso-
ciated with high-grade ACC, correlating with both high
mitotic rate [55] and poor prognosis [56,57]. However,
in multi-variate analysis, when the effects of tumor grade
are considered, Β-catenin has not been shown to have
independent prognostic value [55]. In our series,cortical carcinoma demonstrating positive staining for SF-1 and
ining for SF-1.
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the tumors, including tumors with increased co-
expression of Ki-67.
Inhibin Adrenal inhibins have been shown to stain specif-
ically to the adrenal cortex, and particularly to the zona
reticularis, with weaker staining in the zona fasciculata
and no staining in the zona glomerulosa [58]. Thus, im-
munohistochemical staining for adrenal inhibin expression
is useful to distinguish tumors of adrenal origin. In an
early study, Fetsch et al. demonstrated immunoreactivity
to an adrenal inhibin antibody in all adrenocortical carcin-
omas and adenomas [59]. However, later studies revealed
that a proportion of adrenal tumors are immunonegative,
and that negative staining does not exclude the diagnosis
of ACC [58,60]. High expression of adrenal inhibin is seen
particularly in virilising tumors [58]. Unfortunately, immu-
nopositivity to adrenal inhibin antibodies does not help
distinguish benign from malignant adrenal tumors [58,60].
In our series, only three of eight tumors stained positively
for adrenal inhibin.
IGF Genetic alterations at the 11p15 chromosomal locus
result in an overexpression of IGF-2 in adrenal cortex
cells and are fairly specific to both sporadic and syn-
dromic adrenocortical carcinomas but not adenomas
[43,52,55,61]. Signaling of IGF-2 through its receptor
IGF-1R is thought to play an important role in ACC
tumorigenesis [61]; however, recent in vivo experiments
have demonstrated that isolated over expression of IGF-
2, while specific for malignant cells, is not a driving
factor in ACC malignant progression [52]. Nonetheless,
IGF-2 and IGF-1R antagonists are considered targets for
drug development. IGF-1R antagonists have been tested
in vitro with promising results on human ACC cells
[62,63]. Unfortunately, there has been little success with
IGF antagonists in-vivo [52,64].
Pathogenesis
Syndromal ACC ACC, particularly in children, is often
associated with familial syndromes [65,66]. La-Fraumeni
syndrome, associated with germ line mutations in the
TP53 gene, is present in the majority of children with
adrenocortical tumors but is seen less commonly in
adults [37,65]. Patients with Beckwith-Wiedemann syn-
drome have overexpression of IGF-2 due to loss of the
maternal locus, 11p15 [66]. This mutation is associated
with tumors exclusive to childhood and frequently re-
sults in benign, and rarely malignant, adrenal tumors
[65]. Although the majority of adult ACC has been
thought to be sporadic, there is growing evidence of the
co-existing presence of hereditary cancer syndromes
such as Lynch syndrome [67], multiple endocrineneoplasia type 1 [68], and familial adenomatous polyp-
osis syndrome [56].Staging and prognosis
Identification of tumor features which stratify patients
into high and low risk groups is of upmost clinical
importance. The most obvious is tumor stage which can
be characterized by either the older International Union
Against Cancer system or the newer European Network
for the Study of Adrenal Tumors (ENS@T) system. The
ENS@T system has demonstrated better prognostic
stratification and is currently more widely used. It is
summarized as follows with corresponding 5-year
disease-specific survivals [8,11]:
Stage I - tumor size less than or equal to 5 cm; 82%.
Stage II - tumor size greater than 5 cm; 58%.
Stage III - any tumor size with at least one positive
lymph node or tumor infiltrating into surrounding
adipose tissue or adjacent organs including the presence
of venous tumor thrombus in the inferior vena cava or
renal vein; 55%.
Stage IV - any metastatic disease; 18%.
Further stratifying prognosis beyond disease stage is an
important area of ACC research. Weiss first noted the
importance of mitotic figures as one of the most useful
criteria in distinguishing benign from malignant tumors
[29], and Volante et al. further suggested stratifying pa-
tients into prognostic groups based on mitotic grade with
a cutoff of 9 per 50 HPF indicating a high risk tumor [34].
In metastatic ACC, a higher mitotic rate cutoff of 20 per
50 HPF has been shown to be useful in predicting poor
outcome [69]. Recently, immunohistochemical analysis of
the cellular proliferation marker Ki-67 has been recog-
nized as a more reliable method than the mitotic index in
diagnosing ACC and stratifying prognosis [21,70,71]. Few
other tumor features have been identified as having pos-
sible prognostic importance. One might expect that func-
tioning tumors may have better prognosis due to clinical
cues and earlier diagnosis, however, in addition to higher
patient age at diagnosis, functional tumors are independ-
ently associated with poorer survival [10,20,72]. In meta-
static ACC, involvement of fewer tumoral organs is a
predictor of better disease-specific survival [69]. As dis-
cussed previously, loss of heterozygosity at 17p13 and SF-1
protein staining have been shown to be stage-independent
prognostic factors, while p53 and Β-catenin staining have
not. As such, there are relatively few useful independent
prognostic markers for ACC and a nomogram using only
three variables (age, stage, and surgical status) achieved up
to 80% accuracy for survival prediction in a large cohort
(n = 205) of patients [73].
Table 7 Features of sarcomatoid adrenal cortical carcinomas reported to date
Reference Age Sex Clinical presentation Laterality Size Treatment Time to recurrence Time to death
Okazumi et al. [74] 46 M Abdominal distention + back pain Right 14 cm Right adrenalectomy and nephrectomy
followed by removal of the tumor
thrombus
5 months 206 days
Collina et al. [75] 68 F Abdominal discomfort Right 11 cm Surgical resection followed by radiotherapy
after tumor recurrence
2 months 6 months
Decorato et al. [76] 42 F Abdominal pain Left 19 cm Surgical resection 3 months 7 months
Fischler et al. [77] 29 F Virilization Left 12.5 cm Nephroadrenalectomy and splenectomy
followed by systemic chemotherapy
(cisplatin and etoposide) after recurrence
4 months 8 months
Barksdale et al. [78] 79 F Severe hypertension Right 9 cm Right adrenalectomy and cavotomy 4 months Not reported
Lee et al. [79] 61 M Flank pain + hypertension Right 12 cm Radical nephrectomy and right hepatic
lobectomy
No recurrence noted 2 days
Sturm et al. [7] 31 M Abdominal pain Left 12 cm Adrenalectomy followed by systemic
chemotherapy (VP16-cisplatinum) after
recurrence
2 months 3 months
Coli et al. (2009) [80] 75 F Abdominal pain Left 15 cm Adrenalectomy and splenectomy 3 months 12 months
Feng et al. [81] 72 M Left lumbar pain Left 7.1 cm on
CT scan
Surgical resection Not reported Not reported
Sasaki et al. [82] 45 M Abdominal pain, fever, nausea,
vomiting, anorexia, hypertension
Left 17 cm Radical nephrectomy, splenectomy, distal
pancreatectomy, left partial colectomy, and
wedge biopsy of one hepatic lesion
Hepatic metastasis at
presentation. Locoregional
recurrence at 3 months
3 months
Bertolini et al. [83] 23 F Incidentally during work-up of meta-
static rectal mass
Left 14 cm Left adrenalectomy with systemic
chemotherapy for metastatic rectal cancer
Not reported, however patient
had metastatic lesions on
presentation which were
presumed to be rectal cancer
based on the co-existence of a
metastatic rectal cancer lesion
in the adrenal gland
14 months
Thway et al. [84] 45 M Abdominal bloating + back pain Left 24 cm Left radical nephrectomy and splenectomy
followed by palliative chemotherapy
(vincristine, ifosfamide, carboplatin,
doxorubicin, and etoposide)
Metastatic at presentation 11 months
Yan et al. [85] 72 M Flank pain Right 13 cm Adrenalectomy 2 years 2.5 years
Kao et al. [86] 48 F Abdominal pain + hypokalemia +
weight loss
Right 15 cm Adrenalectomy, partial nephrectomy, and
partial hepatectomy followed by systemic
chemotherapy (cisplatin and ifosfamide)
after distant metastasis
2 months Alive with disease at
7 month follow-up
Mark et al. [87] 58 M Flank pain Right 12 cm Radial nephrectomy followed by eternal
beam radiotherapy to the tumor site




Shaikh et al. [88] 62 F Abdominal pain Right 6.5 cm Adrenalectomy 3 months 4 months
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Despite significant advancement in the past 15 years, ac-
curate diagnosis of ACC remains challenging. The Weiss
criteria remain the gold standard for histopathological
diagnosis, but lack of interobserver reliability in their as-
sessment has led to the emergence of newer techniques
such as the reticulin method. Even in our case series, the
challenge of ACC diagnosis is demonstrated. We identi-
fied one patient where the initial diagnosis of ACC may
have been incorrect on re-examination of histopatho-
logical and reticulin staining criteria (case 5). Immunohis-
tochemistry is a growing area of research and several
markers have been identified to have clinical value. SF-1
overexpression establishes the adrenal cortex as the origin
of adrenal tumors, and the intensity of SF-1 staining is re-
lated to prognosis. Interestingly, in our series, sarcomatoid
regions in cases 3 and 7 did not express SF-1. This raises
the possibility of a de novo mechanism of pathogenesis for
these rare and highly aggressive tumors. Accuracy in
stratification of malignant adrenocortical tumors may be
improved by staining for Β-catenin and p53 which are
more frequently expressed in ACC but have not been
found to have independent prognostic value.
Our case series adds eight cases to the existing literature,
with very high expression of p53 and Β-catenin seen in the
cases with the highest proliferative activity. Sarcomatoid
ACC is extremely rare with very few cases reported in the
literature, and these tumors are usually associated with a
very poor patient outcome. The published cases, in the
English literature, of sarcomatoid ACC are tabulated in
Table 7 [7,74-88]. In summary, as adrenocortical carcin-
oma is a rare disease, we recommend future multicenter
studies with appropriate sample sizes to further evaluate
and identify reliable diagnostic and prognostic markers.
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